HARP Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 17.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Harpoon Therapeutics Share Price & Price History
Current Price: $23.01
Price Change: +0.30 (1.20%)
As of 03/11/2024 01:00 AM ET
Harpoon Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/11/2024 | Merck & Co., Inc. | Major Shareholder | Buy | 21,397,205 | $23.00 | $492,135,715.00 | 1,000 |  |
| 3/23/2023 | Ronald Hunt | Director | Buy | 1,000 | $10,000.00 | $10,000,000.00 | 1,000 | |
Harpoon Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/15/2024 | Blackstone Inc. | 815,000 | $9.27M | 0.0% | N/A | 4.813% |  |
| 2/14/2024 | Commodore Capital LP | 1,500,000 | $17.06M | 1.5% | N/A | 8.859% | |
| 2/14/2024 | New Leaf Venture Partners L.L.C. | 1,859,168 | $21.14M | 17.0% | +489.0% | 10.982% | |
| 2/9/2024 | Franklin Resources Inc. | 1,492,368 | $16.97M | 0.0% | +1,027.8% | 8.815% | |
| 1/31/2024 | abrdn plc | 25,991 | $0.30M | 0.0% | N/A | 0.154% | |
| 11/15/2023 | Kennedy Capital Management LLC | 52,987 | $0.21M | 0.0% | -90.0% | 1.366% | |
| 11/14/2023 | MPM Bioimpact LLC | 319,670 | $1.29M | 0.3% | -90.0% | 8.239% | |
| 11/13/2023 | Acadian Asset Management LLC | 7,670 | $29K | 0.0% | -90.0% | 0.198% | |
| 8/8/2023 | Sequoia Financial Advisors LLC | 63,955 | $45K | 0.0% | -36.0% | 0.199% | |
| 8/7/2023 | Acadian Asset Management LLC | 76,710 | $53K | 0.0% | -32.5% | 0.239% | |
| 5/8/2023 | Bailard Inc. | 63,200 | $47K | 0.0% | N/A | 0.168% | |
| 5/1/2023 | CM Wealth Advisors LLC | 50,354 | $29K | 0.0% | N/A | 0.134% | |
| 4/25/2023 | Sequoia Financial Advisors LLC | 100,000 | $74K | 0.0% | +66.7% | 0.267% | |
| 2/13/2023 | Levin Capital Strategies L.P. | 330,000 | $0.24M | 0.0% | N/A | 0.997% | |
| 11/15/2022 | Piper Sandler & CO. | 580,815 | $0.56M | 0.5% | N/A | 1.754% | |
| 11/14/2022 | Ergoteles LLC | 70,054 | $68K | 0.0% | -23.8% | 0.212% | |
| 9/16/2022 | Federated Hermes Inc. | 132,791 | $0.25M | 0.0% | +45.0% | 0.401% | |
| 8/12/2022 | Franklin Resources Inc. | 1,324,504 | $2.53M | 0.0% | -20.4% | 4.003% | |
| 5/20/2022 | International Biotechnology Trust PLC | 151,445 | $2.77M | 0.6% | -29.6% | 0.458% | |
| 5/13/2022 | Tekla Capital Management LLC | 259,910 | $1.29M | 0.0% | N/A | 0.786% | |
| 5/12/2022 | Connor Clark & Lunn Investment Management Ltd. | 14,872 | $74K | 0.0% | -37.0% | 0.045% | |
| 2/15/2022 | Sender Co & Partners Inc. | 14,252 | $0.11M | 0.1% | N/A | 0.044% | |
| 2/15/2022 | Kennedy Capital Management Inc. | 129,766 | $0.98M | 0.0% | N/A | 0.396% | |
| 2/14/2022 | Point72 Asset Management L.P. | 650,000 | $4.91M | 0.0% | N/A | 1.985% | |
| 2/14/2022 | GSA Capital Partners LLP | 35,266 | $0.27M | 0.0% | +42.0% | 0.108% | |
| 2/10/2022 | Candriam Luxembourg S.C.A. | 809,568 | $6.11M | 0.0% | +65.4% | 2.472% | |
| 2/10/2022 | Panagora Asset Management Inc. | 85,059 | $0.64M | 0.0% | +113.0% | 0.260% | |
| 2/10/2022 | Connor Clark & Lunn Investment Management Ltd. | 23,595 | $0.18M | 0.0% | +110.2% | 0.072% | |
| 2/8/2022 | Northern Trust Corp | 191,251 | $1.44M | 0.0% | -3.4% | 0.584% | |
| 1/28/2022 | Allspring Global Investments Holdings LLC | 4,621 | $34K | 0.0% | N/A | 0.014% | |
| 11/16/2021 | Schonfeld Strategic Advisors LLC | 84,272 | $0.67M | 0.0% | +41.1% | 0.258% | |
| 11/16/2021 | Squarepoint Ops LLC | 14,703 | $0.12M | 0.0% | N/A | 0.045% | |
| 11/16/2021 | Two Sigma Advisers LP | 377,500 | $2.98M | 0.0% | N/A | 1.155% | |
| 11/16/2021 | Two Sigma Investments LP | 406,470 | $3.21M | 0.0% | N/A | 1.244% | |
| 11/16/2021 | Millennium Management LLC | 602,752 | $4.76M | 0.0% | +994.7% | 1.845% | |
| 11/15/2021 | Cubist Systematic Strategies LLC | 45,121 | $0.36M | 0.0% | +356.9% | 0.138% | |
| 11/12/2021 | Geode Capital Management LLC | 380,213 | $3M | 0.0% | +8.0% | 1.164% | |
| 11/10/2021 | Goldman Sachs Group Inc. | 87,398 | $0.69M | 0.0% | -60.8% | 0.268% | |
| 11/10/2021 | Citigroup Inc. | 3,817 | $30K | 0.0% | -96.4% | 0.012% | |
Data available starting January 2016
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Read More on Harpoon Therapeutics
Today's Range
Now: $23.01
52 Week Range
Now: $23.01
Volume
N/A
Average Volume
1,516,200 shs
Market Capitalization
$389.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.11
Who are the company insiders with the largest holdings of Harpoon Therapeutics?
